Inventiva S.A. ADR (IVA) Stock Price, Quote & News

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 3 80 44 75 00

Website: inventivapharma.com

Address:

50 rue de Dijon, Daix, France

BioTuesdays Apr. 27 at 4:09 PM

$IVA has appointed three new members to its leadership team, including Axel-Sven Malkomes as chief financial officer, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. https://biotuesdays.com/2026/04/27/inventiva-builds-c-suite-ahead-of-phase-3-mash-readout/

0 · Reply

Quantumup Apr. 23 at 3:34 PM

$IVA: pan-PPAR agonist Lanifibranor is under investigation in a Quintuple Agonist Study. $LLY $NVO Article Title: New quintuple agonist shows promise for treating obesity and type 2 diabetes: https://www.news-medical.net/news/20250921/New-quintuple-agonist-shows-promise-for-treating-obesity-and-type-2-diabetes.aspx

1 · Reply

Quantumup Apr. 23 at 2:58 PM

New *Quintuple Agonist data @ #ADA2026 in a Late Breaker Poster Session: Title: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats $LLY $NVO $IVA https://eppro02.ativ.me/web/planner.php?id=ADA26

0 · Reply

OfficialStocktwitsUser Apr. 22 at 5:07 PM

$IVA RSI: 48.89, MACD: -0.1339 Vol: 0.25, MA20: 5.54, MA50: 5.98 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Jonita Apr. 22 at 11:37 AM

$IVA in in in

0 · Reply

SuperGreenToday Apr. 18 at 2:11 AM

$IVA

0 · Reply

pixbillye Apr. 17 at 6:17 PM

$IVA https://ilvo.vlaanderen.be/nl/nieuws/alga-care-onderzoekt-potentieel-van-microalgen-tegen-leververvetting-een-groeiend-probleem-voor-1-op-de-3-belgen fresh from the press

1 · Reply

BioRich Apr. 15 at 2:06 PM

$IVA @POPEYE832 While I appreciate the logic here of go/no-go for the $IVA trial, I believe that they will be successful and ultimately take on a massive part of the market. They are the leader in Fibrosis Improvement, which, I believe is the hardest to achieve, most highly sought after liver disease ailment. Yes, the space has several names, but $IVA, to date, is statistically the leader. $MDGL is the clear leader in the space as they were first to market and revenue generating, but I think $IVA gets a massive portion of the fibrosis market. Time will tell, but I'm very happy and comfortable with $IVA. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply

BioRich Apr. 15 at 1:56 PM

$IVA Wish I had bought more on the dip. Hadn't digested why it dipped but I'm happy for those that did and have made great money. Since I'm being lazy, does anyone know what exactly caused the dip? I saw a filing, but didn't think it was bad. Thanks in advance!

1 · Reply

POPEYE832 Apr. 13 at 11:12 AM

$IVA, with only one drug in trials, if the results are bad, the stock will crash; if they are good but not outstanding, the stock will still crash. There’s nothing else in the company’s pipeline, and there’s a lot of competition, including a company called MGDL that is already on the market. Personally, love this scenario.

1 · Reply

Inventiva (IVA) Enhances Leadership Team with New Appointments

Apr 22, 2026, 4:00 PM EDT - 7 days ago

Market Cap	751.65M
Revenue (ttm)	8.97M
Net Income (ttm)	-400.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,466.78%
Debt to Equity Ratio	-2.10

Volume	146,800
Avg Vol	363,956
Day's Range	N/A - N/A
Shares Out	145.95M
Stochastic %K	1%
Beta	0.78
Analysts	Strong Sell
Price Target	$15.06